Synthetic organic

AZ7188.

InformationAZ876 AZ876 is a novel high-affinity Liver X Receptor (LXR) agonist with Ki values of 0.007 μM and 0.011 μM for human LXRα and LXRβ respectively.TargetsLXRα : LXRβ 0.007 μM(Ki): 0.011 μM(Ki)In vitroIn binding assays, AZ876 is 25-fold and

InformationAZ876 AZ876 is a novel high-affinity Liver X Receptor (LXR) agonist with Ki values of 0.007 μM and 0.011 μM for human LXRα and LXRβ respectively.TargetsLXRα : LXRβ 0.007 μM(Ki): 0.011 μM(Ki)In vitroIn binding assays, AZ876 is 25-fold and

InformationAZ876 AZ876 is a novel high-affinity Liver X Receptor (LXR) agonist with Ki values of 0.007 μM and 0.011 μM for human LXRα and LXRβ respectively.TargetsLXRα : LXRβ 0.007 μM(Ki): 0.011 μM(Ki)In vitroIn binding assays, AZ876 is 25-fold and

InformationAZ876 AZ876 is a novel high-affinity Liver X Receptor (LXR) agonist with Ki values of 0.007 μM and 0.011 μM for human LXRα and LXRβ respectively.TargetsLXRα : LXRβ 0.007 μM(Ki): 0.011 μM(Ki)In vitroIn binding assays, AZ876 is 25-fold and

InformationAZ876 AZ876 is a novel high-affinity Liver X Receptor (LXR) agonist with Ki values of 0.007 μM and 0.011 μM for human LXRα and LXRβ respectively.TargetsLXRα : LXRβ 0.007 μM(Ki): 0.011 μM(Ki)In vitroIn binding assays, AZ876 is 25-fold and

AZ8838 is a potent, competitive, allosteric, orally active non-peptide small molecule antagonist of PAR2 with a pKi of 6.4 for hPAR2.

AZ8838 is a potent, competitive, allosteric, orally active non-peptide small molecule antagonist of PAR2 with a pKi of 6.4 for hPAR2.

AZ8838 is a potent, competitive, allosteric, orally active non-peptide small molecule antagonist of PAR2 with a pKi of 6.4 for hPAR2.

AZ8838 is a potent, competitive, allosteric, orally active non-peptide small molecule antagonist of PAR2 with a pKi of 6.4 for hPAR2.

aza-THIP.

aza-THIP.